Residual disease after induction Therapy in Childhood ALL.: 'a highly significant prognostic factor'

被引：0
|
作者：
Cavé, H
ten Bosch, JV
Suciu, S
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1989 / 1990
页数：2
相关论文
共 50 条
  • [41] Prognostic value of real time quantitative minimal residual disease detection within an in-vitro-drug-resistance-profile stratified therapeutic regimen in childhood precursor B-cell ALL.
    zur Stadt, U
    Naecker, A
    Escherich, G
    Golta, S
    Pieters, R
    den Boer, M
    Janka, G
    Kabisch, H
    [J]. BLOOD, 2003, 102 (11) : 605A - 606A
  • [42] Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome
    Zeidler, Lutz
    Zimmermann, Martin
    Moericke, Anja
    Meissner, Barbara
    Bartels, Dorothee
    Tschan, Christoph
    Schrauder, Andre
    Cario, Gunnar
    Goudeva, Lilia
    Jaeger, Sarah
    Ratei, Richard
    Ludwig, Wolf-Dieter
    Teigler-Schlegel, Andrea
    Skokowa, Julia
    Koehler, Rolf
    Bartram, Claus R.
    Riehm, Hansjoerg
    Schrappe, Martin
    Welte, Karl
    Stanulla, Martin
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (03): : 402 - 409
  • [43] The Prognostic Significance of Minimal Residual Disease Detection after Induction and ASCT to the Patients with Multiple Myeloma
    Yao, Weiqin
    Zhu Mingqing
    Yao Feirong
    Yan, Lingzhi
    Jin, Song
    Shang, Jingjing
    Yao, Ying
    Yan, Shuang
    Wu, Depei
    Fu, ChengCheng
    [J]. BLOOD, 2018, 132
  • [44] Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy
    Karol, Seth E.
    Coustan-Smith, Elaine
    Cao, Xueyuan
    Shurtleff, Sheila A.
    Raimondi, Susana C.
    Choi, John K.
    Ribeiro, Raul C.
    Dahl, Gary V.
    Bowman, W. Paul
    Taub, Jeffrey W.
    Degar, Barbara
    Leung, Wing
    Downing, James R.
    Pui, Ching-Hon
    Rubnitz, Jeffrey E.
    Campana, Dario
    Inaba, Hiroto
    [J]. BLOOD, 2013, 122 (21)
  • [45] Detection of minimal residual disease in childhood acute lymphoblastic leukemia after termination of therapy
    Wu, NH
    Lu, SG
    Zhu, P
    Peng, YY
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1996, 13 (03) : 257 - 263
  • [46] Flow cytometry and molecular methods reach similar sensitivity in detection of minimal residual disease in ALL.
    Pisa, P
    Malec, M
    Bjorklund, E
    Soderha, S
    PorwitMacDonald, A
    [J]. BLOOD, 1997, 90 (10) : 3725 - 3725
  • [47] BCR-ABL AccuQuant® assays for monitoring minimal residual disease in patients with CML and ALL.
    Wang, JQ
    [J]. BLOOD, 2000, 96 (11) : 111A - 111A
  • [48] Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy
    Mueller, Hannah Deborah
    Posch, Florian
    Suppan, Christoph
    Bargfrieder, Ute
    Gumpoldsberger, Melanie
    Hammer, Robert
    Hauser, Hubert
    Dandachi, Nadia
    Prein, Kurt
    Stoeger, Herbert
    Lax, Sigurd
    Balic, Marija
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (13) : 4274 - 4283
  • [49] MINIMAL RESIDUAL DISEASE (MRD) ANALYSIS OF ADULT AND CHILDHOOD ALL
    COYLE, L
    YAXLEY, JC
    COLESINCLAIR, M
    CHIM, JS
    CANNELL, P
    WRIGHT, F
    MEHTA, AB
    PRENTICE, HG
    HOFFBRAND, AV
    FORONI, L
    [J]. BLOOD, 1994, 84 (10) : A300 - A300
  • [50] Minimal residual disease monitoring: a new era for childhood ALL
    Schnittger, Susanne
    [J]. LANCET ONCOLOGY, 2015, 16 (04): : 362 - 364
12345